Market capitalization | $14.25m |
Enterprise Value | $8.60m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.87 |
P/S ratio (TTM) P/S ratio | 3.10 |
P/B ratio (TTM) P/B ratio | 4.15 |
Revenue growth (TTM) Revenue growth | 11.18% |
Revenue (TTM) Revenue | $4.60m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast InMed Pharmaceuticals Inc:
1 Analyst has issued a forecast InMed Pharmaceuticals Inc:
Jun '24 |
+/-
%
|
||
Revenue | 4.60 4.60 |
11%
11%
|
|
Gross Profit | 0.50 0.50 |
56%
56%
|
|
EBITDA | -7.80 -7.80 |
0%
0%
|
EBIT (Operating Income) EBIT | -8.40 -8.40 |
0%
0%
|
Net Profit | -7.68 -7.68 |
3%
3%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
InMed Pharmaceuticals, Inc. engages in the research and development of cannabinoid-based therapies and biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It offers pipeline of medications that target diseases with unmet medical needs, such as epidermolysis bullosa, glaucoma, and orofacial pain. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
Head office | Canada |
CEO | Eric Adams |
Employees | 13 |
Founded | 1981 |
Website | www.inmedpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.